Drug intelligence / Profile preview

GXV-006

Development stage: Preclinical
Lead developer: GEXVal
Modality: Small Molecules
Administration: Oral

Overview

GXV-006 is an investigational small molecule drug candidate being developed by GEXVal for the treatment of non-motor symptoms of Parkinson's disease (PD), such as sleep disorders, autonomic dysfunction, depression, anxiety, and cognitive impairment. The program was selected to receive research funding of approximately $1.3 million from The Michael J. Fox Foundation (MJFF) under its Parkinson's Disease Therapeutics Pipeline Program to support preclinical research using multiple Parkinson's disease animal models. GXV-006 was identified using GEXVal's proprietary AI-driven pharmacoinformatics platform, RePhaIND, which is designed to discover hidden therapeutic potential in existing drug candidates.

Targets

Class A G protein-coupled receptor

Beyond the preview

Go deeper on GXV-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GXV-006.

Explore the full profile